Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Who We Help
  2. Insights
  3. Events
  4. Contact Us
MAIN/search
MAIN/Who We Help
Who We Help/
WHO WE HELP
  • Pharmaceutical Manufacturers
  • Emerging Biopharma
  • MedTech
  • Financial Institutions
  • Government and Public Health
  • Health Plans
  • Hospital and Health Systems
  • Insurers and Risk
  • Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers

Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.

Discover More
Pharmaceutical Manufacturers
Emerging Biopharma (Global page)

Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.

Discover Innovations
MedTech

Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.

Explore MedTech
MedTech
Financial Institutions

Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.

Access Insights
Government and Public Health

Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.

Unlock Innovations
Government and Public Health
Health Plans

Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.

Navigate Health Plans
Hospital and Health Systems

Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.

Streamline Decisions
Hospital and Health Systems
Insurers and Risk

Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.

Uncover More
Medical Specialty and Patient Advocacy

Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.

Explore Now
MAIN/Insights
Insights/
U.S. PROGRESS POINT

A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.

LEARN MORE
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS

PODCASTS

"Discover the future through our enlightening podcasts available in the United States.

EXPLORE PODCASTS

FACT SHEET

"IQVIA AI Medical Record Review

LEARN MORE

BLOG

"Decoding DSCSA: Ensuring Compliance in the Pharmaceutical Supply Chain

READ MORE
MAIN/Events
Events/
ON-DEMAND WEBINARS

Visit our library of on-demand webinars.

WATCH ON-DEMAND WEBINARS
UPCOMING EVENTS & WEBINARS

View our upcoming events and webinars.

DISCOVER EVENTS & WEBINARS

EVENT

"26th Controlled Substances and State Regulatory Conference

REGISTER NOW
MAIN/Contact Us
Contact Us/
Blog
Controlled Substances Destruction: The DEA’s Call for Input
Mark Caverly, Sr. Consultant, U.S. Regulatory Compliance, IQVIA
Mar 08, 2024

It may seem obvious that U.S. drug makers and regulators don’t want pharmaceutical controlled drugs that were “destroyed” to be recoverable. The risks of such a scenario are apparent.

Think of the places in which drugs are legally used, such as hospitals, doctors’ offices, and even research and development labs. Invariably, there are amounts left over that need to be destroyed, or made “non-retrievable,” to prevent diversion and to protect public health and safety. But establishing protocols for disposal of those drugs can be challenging and the government believes there may be multiple viable alternatives.

While incineration has been the historical go-to destruction method to achieve that end, the U.S. Drug Enforcement Administration (DEA) is seeking input about alternative processes to accomplish the same result that are consistent with state and environmental laws and regulations. 

In an Advance Notice of Proposed Rulemaking (ANPRM) published in October 2023, titled Controlled Substance Destruction Alternatives to Incineration, the DEA is seeking comments regarding “methods of destruction . . .  other than incineration which may meet the disposal requirements of DEA registrants, and to promote the public exchange of technology and process development information . . .” The comment period ends April 1, 2024.   

Those who may choose to provide comment must consider the DEA’s results-oriented definition of non-retrievable. It does not address process:

“Non-retrievable means, for the purpose of destruction, the condition or state to which a controlled substance shall be rendered following a process that permanently alters that controlled substance's physical or chemical condition or state through irreversible means and thereby renders the controlled substance unavailable and unusable for all practical purposes. The process to achieve a non-retrievable condition or state may be unique to a substance's chemical or physical properties. A controlled substance is considered “non-retrievable” when it cannot be transformed to a physical or chemical condition or state as a controlled substance or controlled substance analogue. The purpose of destruction is to render the controlled substance(s) to a non-retrievable state and thus prevent diversion of any such substance to illicit purposes.”

Ten questions compose the bulk of the DEA’s notice and help shape the issue and potential response. The DEA instructs:

“Please identify destruction methods or technology currently being utilized or developed to render the controlled substances non-retrievable. For each method or technology identified, please include:

1. If known, the potential users of this method or technology.

2. A detailed description of the method of destruction or technical process utilized to achieve the non-retrievable standard. Does this method or technology involve incineration at any point to attain the non-retrievable standard?

3. The controlled substance(s) to which the method of destruction or technology to render the controlled substance(s) non-retrievable may be applicable.

4. If known, list any controlled substances that will not be rendered non-retrievable by this method.

5. The volume or throughput (per hour) required to render the controlled substance non-retrievable.

6. The registrant's anticipated cost to execute, implement, or utilize the method of destruction or technology discussed above.

7. The analytical process utilized to evaluate the effectiveness of the method of destruction or technology. Provide the analytical results validating attainment of the non-retrievable standard.

8. The characteristics or constituents of any by-products or waste generated through the process used to render the controlled substance non-retrievable. Provide the waste profile sheet or similar documentation showing analytical results of the by-products or waste generated.

9. The disposal process of the by-products or waste generated.

10. The Federal, state, or local regulatory requirements associated with the disposal process and/or disposal of the by-products or waste.”

To learn more about the DEA’s call for comments, click the link to the DEA’s ANPRM to include your comments: 

https://www.regulations.gov/document/DEA-2023-0148-0001

Should you choose to contribute input, provide detailed information that clearly communicates and supports your comments. Proprietary information can be redacted, if requested.

DEA FDA Regulatory Consulting

Whether it’s requirements of the DEA, the FDA, or state regulations that are keeping you up at night, IQVIA has the solutions to help you stay compliant.
learn more

Related solutions

Contact Us